Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Vaccines
•
Allergy & Immunology
•
Primary Care
How long do you counsel patients to wait after rituximab therapy before getting live vaccines?
Related Questions
Do mRNA vaccines lead to increased rates of acute/chronic urticaria?
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Do patients with a PEG allergy have a contraindication to receiving mRNA vaccines?
How often do you find a food allergy on a skin test in an EoE patient that when avoided will result in significant resolution of EoE?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
What treatments do you consider for cholinergic urticaria refractory to high dose H1 blockers and omalizumab?
What are the implications of checking post-vaccine titers after administration of Prevnar 20 compared to PPSV23?
How long would you treat severe eosinophilic asthma/pneumonia with q4week anti-IL5 therapy prior to tapering?
What are your practice recommendations regarding live vaccinations in infants/children of women who are currently on DMARDs and are breastfeeding?
